News | May 28, 2025
Sanjivani Paranteral posts Q4 FY25 at Rs. 2.19 Cr
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Akums invested Rs. 272 crore in capital expenditure during FY25
The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
Allopurinol is used to prevent or lower high uric acid levels in the blood
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
Isotretinoin capsules are indicated to treat severe, disfiguring nodular acne
Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards
Subscribe To Our Newsletter & Stay Updated
